FOSTER CITY, CA--(MARKET WIRE)--Aug 7, 2008 -- SciClone Pharmaceuticals, Inc. (NasdaqGM:SCLN - News) today announced the appointment of Jeffery Lange as Vice President, Business Development effective August 11, 2008. In this position, Mr. Lange will leverage his significant biopharmaceutical industry experience to lead business development activities for SciClone's pipeline of product candidates in viral infectious diseases and oncology as well as its business in China. Mr. Lange will report to Friedhelm Blobel, Ph.D., President and Chief Executive Officer of SciClone.

"Jeff's wealth of business development experience, demonstrated success, and diverse international financial background is of important value to SciClone," said Dr. Blobel. "As we continue to develop our pipeline, manage multiple out-licensing and partnership opportunities for our lead compound, thymalfasin, and in-license additional products for China, his experience at driving product and licensing deals will be essential."

Mr. Lange served most recently as Director, Business Development & Licensing Finance at Novartis in East Hanover, NJ where he was responsible for licensing, divestiture, co-marketing, and merger & acquisition valuation as part of a global negotiation team for Novartis Pharma General Medicines. Prior to that, Mr. Lange held various positions within Novartis including the Head of Strategic Financial Planning in Novartis' Pharma General Medicine group in Basel, Switzerland, and Manager of Business Development and Planning at Novartis Agribusiness. Earlier in his career, Mr. Lange held a variety of positions in planning and analysis, finance and accounting.

Mr. Lange earned a Master of Business Administration with a specialization in Finance from the University of Chicago and a Bachelor of Business Administration in Accounting from the University of Iowa.

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in a late-stage clinical trial for the treatment of hepatitis C, and successfully completed a phase 2 clinical trial in malignant melanoma. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage and broaden its portfolio in the rapidly growing Chinese market by in-licensing or acquiring the marketing rights to other products, such as DC Bead(TM). For the U.S. market, SciClone's other clinical-stage drug development candidates are RP101 for the treatment of pancreatic cancer and SCV-07 for the treatment of hepatitis C. For more information about SciClone, visit www.sciclone.com.

     Corporate Contact:
     Ana Kapor
     SciClone Pharmaceuticals, Inc.
     650.358.3437
     Email Contact